CN112500386A - 基于吡啰红肟的近红外HClO荧光探针、制备及其应用 - Google Patents
基于吡啰红肟的近红外HClO荧光探针、制备及其应用 Download PDFInfo
- Publication number
- CN112500386A CN112500386A CN202011361513.7A CN202011361513A CN112500386A CN 112500386 A CN112500386 A CN 112500386A CN 202011361513 A CN202011361513 A CN 202011361513A CN 112500386 A CN112500386 A CN 112500386A
- Authority
- CN
- China
- Prior art keywords
- fluorescent probe
- cells
- pyox
- hclo
- preparing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000007850 fluorescent dye Substances 0.000 title claims abstract description 25
- QWPPOHNGKGFGJK-UHFFFAOYSA-N hypochlorous acid Chemical compound ClO QWPPOHNGKGFGJK-UHFFFAOYSA-N 0.000 title claims abstract description 22
- 150000002923 oximes Chemical class 0.000 title claims abstract description 11
- 238000002360 preparation method Methods 0.000 title abstract description 8
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 60
- 201000011510 cancer Diseases 0.000 claims abstract description 27
- 239000000523 sample Substances 0.000 claims abstract description 18
- 238000006243 chemical reaction Methods 0.000 claims abstract description 13
- 238000001514 detection method Methods 0.000 claims abstract description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 27
- 239000000543 intermediate Substances 0.000 claims description 26
- 239000000243 solution Substances 0.000 claims description 22
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 21
- JNELGWHKGNBSMD-UHFFFAOYSA-N xanthone Chemical compound C1=CC=C2C(=O)C3=CC=CC=C3OC2=C1 JNELGWHKGNBSMD-UHFFFAOYSA-N 0.000 claims description 13
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- 238000001914 filtration Methods 0.000 claims description 10
- 239000012074 organic phase Substances 0.000 claims description 9
- 238000004440 column chromatography Methods 0.000 claims description 8
- 238000001035 drying Methods 0.000 claims description 8
- 238000001704 evaporation Methods 0.000 claims description 8
- 238000003756 stirring Methods 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 6
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 claims description 6
- 238000010791 quenching Methods 0.000 claims description 6
- 238000010992 reflux Methods 0.000 claims description 6
- 239000007832 Na2SO4 Substances 0.000 claims description 5
- 230000003834 intracellular effect Effects 0.000 claims description 5
- NXPHGHWWQRMDIA-UHFFFAOYSA-M magnesium;carbanide;bromide Chemical compound [CH3-].[Mg+2].[Br-] NXPHGHWWQRMDIA-UHFFFAOYSA-M 0.000 claims description 5
- 229910052938 sodium sulfate Inorganic materials 0.000 claims description 5
- 238000005406 washing Methods 0.000 claims description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N CHCl3 Substances ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 3
- 238000001816 cooling Methods 0.000 claims description 3
- 239000012043 crude product Substances 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 239000000047 product Substances 0.000 claims description 3
- 230000000171 quenching effect Effects 0.000 claims description 3
- 229920006395 saturated elastomer Polymers 0.000 claims description 3
- 239000002904 solvent Substances 0.000 claims description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 3
- 239000007864 aqueous solution Substances 0.000 claims description 2
- 239000002808 molecular sieve Substances 0.000 claims description 2
- 239000012299 nitrogen atmosphere Substances 0.000 claims description 2
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 claims description 2
- -1 xanthone compound Chemical class 0.000 claims 1
- 230000004069 differentiation Effects 0.000 abstract description 4
- 239000000975 dye Substances 0.000 abstract description 2
- 230000004044 response Effects 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 97
- 238000003384 imaging method Methods 0.000 description 15
- 239000003642 reactive oxygen metabolite Substances 0.000 description 15
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 13
- 239000002953 phosphate buffered saline Substances 0.000 description 13
- 241000699670 Mus sp. Species 0.000 description 11
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 9
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 8
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 6
- 238000005160 1H NMR spectroscopy Methods 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 5
- 238000004113 cell culture Methods 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 238000000799 fluorescence microscopy Methods 0.000 description 5
- 229960003180 glutathione Drugs 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 4
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 4
- 230000003013 cytotoxicity Effects 0.000 description 4
- 231100000135 cytotoxicity Toxicity 0.000 description 4
- 238000002073 fluorescence micrograph Methods 0.000 description 4
- 238000011503 in vivo imaging Methods 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 210000003462 vein Anatomy 0.000 description 4
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 3
- 108010087230 Sincalide Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000010609 cell counting kit-8 assay Methods 0.000 description 3
- 239000008367 deionised water Substances 0.000 description 3
- 229910021641 deionized water Inorganic materials 0.000 description 3
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 3
- 230000005284 excitation Effects 0.000 description 3
- 238000002189 fluorescence spectrum Methods 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 238000002271 resection Methods 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- KZDCMKVLEYCGQX-UDPGNSCCSA-N 2-(diethylamino)ethyl 4-aminobenzoate;(2s,5r,6r)-3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid;hydrate Chemical compound O.CCN(CC)CCOC(=O)C1=CC=C(N)C=C1.N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 KZDCMKVLEYCGQX-UDPGNSCCSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 108010024636 Glutathione Proteins 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- 229910002651 NO3 Inorganic materials 0.000 description 2
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 2
- 239000004107 Penicillin G sodium Substances 0.000 description 2
- 238000002679 ablation Methods 0.000 description 2
- 238000000862 absorption spectrum Methods 0.000 description 2
- 230000008033 biological extinction Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- WQYVRQLZKVEZGA-UHFFFAOYSA-N hypochlorite Chemical compound Cl[O-] WQYVRQLZKVEZGA-UHFFFAOYSA-N 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- IFTVAQUNDKGWDD-UHFFFAOYSA-M mitoTracker Green FM Chemical compound [Cl-].O1C2=CC=CC=C2N(C)C1=CC=CC(=[N+](C1=CC(Cl)=C(Cl)C=C11)C=2C=CC(CCl)=CC=2)N1C1=CC=C(CCl)C=C1 IFTVAQUNDKGWDD-UHFFFAOYSA-M 0.000 description 2
- 238000011580 nude mouse model Methods 0.000 description 2
- 235000019369 penicillin G sodium Nutrition 0.000 description 2
- 229940056360 penicillin g Drugs 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 102200082402 rs751610198 Human genes 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- 208000021959 Abnormal metabolism Diseases 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 229920002449 FKM Polymers 0.000 description 1
- 241000025505 Pyrrosia Species 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 230000006682 Warburg effect Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000006536 aerobic glycolysis Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 210000001099 axilla Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000000295 emission spectrum Methods 0.000 description 1
- 230000005281 excited state Effects 0.000 description 1
- 238000012921 fluorescence analysis Methods 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011337 individualized treatment Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000005865 ionizing radiation Effects 0.000 description 1
- 238000006317 isomerization reaction Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000006371 metabolic abnormality Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- CMFNMSMUKZHDEY-UHFFFAOYSA-M peroxynitrite Chemical compound [O-]ON=O CMFNMSMUKZHDEY-UHFFFAOYSA-M 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 230000004960 subcellular localization Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/78—Ring systems having three or more relevant rings
- C07D311/80—Dibenzopyrans; Hydrogenated dibenzopyrans
- C07D311/82—Xanthenes
- C07D311/90—Xanthenes with hydrocarbon radicals, substituted by amino radicals, directly attached in position 9
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
- A61K49/0043—Fluorescein, used in vivo
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K11/00—Luminescent, e.g. electroluminescent, chemiluminescent materials
- C09K11/06—Luminescent, e.g. electroluminescent, chemiluminescent materials containing organic luminescent materials
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
- G01N21/6428—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes"
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K2211/00—Chemical nature of organic luminescent or tenebrescent compounds
- C09K2211/10—Non-macromolecular compounds
- C09K2211/1018—Heterocyclic compounds
- C09K2211/1025—Heterocyclic compounds characterised by ligands
- C09K2211/1088—Heterocyclic compounds characterised by ligands containing oxygen as the only heteroatom
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Optics & Photonics (AREA)
- Epidemiology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Materials Engineering (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
技术领域
本发明涉及荧光探针领域,具体涉及一种基于吡啰红肟的近红外HClO荧光探针、制备及其应用。
背景技术
癌症与正常细胞/组织的区别对癌症的早期诊断和治疗至关重要。在目前已经开发的肿瘤影像工具中,基于荧光探针的肿瘤成像技术因其具有可视化、无侵袭性、高灵敏度、无电离辐射、活体实时成像等优点而受到广泛关注,此类荧光探针最常见的设计策略是将荧光团与配体,包括化学分子、多肽、蛋白质和抗体等,进行化学偶联,这些配体可以特异性地结合到癌细胞过表达的表面标记物上。利用这类探针来影像癌症和正常细胞/组织的差异有助于患者个体化治疗,但由于癌细胞和肿瘤的遗传或表型异质性,利用这种差异来诊断广谱性癌症依然很困难。
因此,科研工作者把注意力集中在肿瘤的异常代谢上,即有氧糖酵解(也称为Warburg效应),癌细胞这种特殊的代谢方式会创造一个与癌症类型无关的癌细胞特有的微环境,如细胞外pH值降低、细胞内谷胱甘肽(GSH)和活性氧(ROS)水平升高等。然而,由于癌细胞和正常细胞之间的细胞外pH和细胞内GSH水平并没有太大的差异(pH分别为6.5和7.4;谷胱甘肽均为mM级别),迄今为止,通过该策略达到区分目的的例子非常少。
相反,癌细胞内的ROS浓度,包括O2 -、H2O2、OH•、ONOO-和ClO-等,大约是正常细胞的10倍,因此,ROS敏感型探针应该对癌细胞比对正常细胞/组织具有更高的敏感性。事实上,癌细胞的这一特性已被广泛应用在癌症治疗相关的ROS响应药物递送系统。尽管在过去的十年中有大量的ROS荧光探针被报道,但是到目前为止,只有少数的ROS荧光探针可以达到区分癌和正常细胞/组织的效果。其中一个可能的原因是由于探针敏感性不足,这使得大多数探针难以对癌细胞中本底的ROS作出响应;另一个原因可能是由于大部分ROS探针的吸收和发射波长位于可见区,与近红外光(650-900 nm)相比,可见光的组织穿透性差,严重限制了该类探针在组织或活体中的成像应用。因此,开发能够同时克服以上缺点的ROS荧光探针将对于诊断广谱性肿瘤具有重要意义。
发明内容
本发明提出了一种基于吡啰红肟的近红外HClO荧光探针、制备及其应用,该探针在近红外区显示出对HClO的快速、高选择性和高灵敏的荧光响应。这些优异的特性使其在区分癌细胞和正常细胞/组织的实际应用中获得成功。
实现本发明的技术方案是:
一种基于吡啰红肟的近红外HClO荧光探针(PyOX),荧光探针的结构式如下:
所述的荧光探针的制备方法,步骤如下:
(1)在0 °C、氮气环境中,将氧杂蒽酮溶于无水四氢呋喃中,向上述反应液中缓慢加入甲基溴化镁的THF溶液,室温搅拌过夜,反应结束后用水猝灭、DCM萃取、减压去除溶剂,得到的产物重新溶解在乙腈和高氯酸的水溶液中,搅拌10分钟后再次用DCM萃取,有机相用无水Na2SO4干燥,过滤蒸发得到粗产品,柱色谱纯化得到中间体2;
(2)将步骤(1)得到的中间体2和I2溶解于CHCl3,回流反应0.5 h,向上述溶液中加入二甲亚砜继续回流48 h,反应结束后冷却至室温,混合物用饱和Na2S2O3淬灭、二氯甲烷萃取,有机相经无水Na2SO4干燥、过滤蒸发,柱色谱纯化得到中间体3;
(3)将步骤(2)得到的中间体3、NH2OH·HCl和4Å分子筛加到乙腈中,室温搅拌6 h,反应液经过滤、水洗、DCM萃取,有机相经干燥、过滤蒸发,柱色谱纯化得到探针PyOX。
所述步骤(1)中氧杂蒽酮的结构式如下:
所述中间体2的结构式如下:
所述中间体3的结构式如下:
所述步骤(1)中氧杂蒽酮和甲基溴化镁的摩尔比为1:1.25;步骤(2)中间体2和I2的摩尔比为1:1,步骤(3)中间体3和盐酸羟氨的摩尔比为1:10。
所述的荧光探针在近红外区域检测HClO的应用,最低检测限为2.4 nM。
本发明的探针的合成及对HClO的传感机理所示:
所述的荧光探针在区分癌细胞和正常细胞中的应用,通过检测细胞内ROS水平区分癌细胞和正常细胞。
使用PyOX探针区分癌细胞和正常细胞/组织的原理如图所示:
本发明的有益效果是:本发明将肟反应基团与吡啰红荧光团的9位相结合构建的探针,在近红外区域对HClO显示出快速、显著的荧光off-on响应,灵敏度极高,已成功应用于癌细胞/组织与正常细胞/组织的区分。
附图说明
为了更清楚地说明本发明实施例或现有技术中的技术方案,下面将对实施例或现有技术描述中所需要使用的附图作简单地介绍,显而易见地,下面描述中的附图仅仅是本发明的一些实施例,对于本领域普通技术人员来讲,在不付出创造性劳动的前提下,还可以根据这些附图获得其他的附图。
图1为实施例中间产物2的1H NMR图;
图2为实施例中间产物2的13C NMR图;
图3为实施例中间产物2的HRMS图;
图4为实施例中间产物3的1H NMR图;
图5为实施例中间产物3的13C NMR图;
图6为实施例中间产物3的HRMS图;
图7为PyOX的1H NMR图;
图8为PyOX的13C NMR;
图9为PyOX的HRMS图;
图10(A, B)为PyOX(2 μM)经ClO-处理前后的吸收和发射光谱图,B中插图为PyOX(2 μM)经2当量ClO-处理后在680 nm处荧光强度的变化;C为随着ClO-用量的增加,PyOX(2μM)荧光光谱的变化;D为PyOX(2 μM)经不同物质(包括2 μM的ClO-和ONOO-;20 μM 的O2 ·, ·OH, 1O2, H2O2和NO;200 μM的Cys, Hcy, GSH, SH-和HSO3 -;200 μM的HCO3 -, AcO-, NO3 -,NO2 -, Cl-, Cu2+ , Ca2+ , Fe2+ , Fe3+和Zn2+)处理后的荧光光谱变化;
图11(A) 预先用PyOX(2 μM)处理20分钟后正常细胞和癌细胞的荧光成像图;(B)为(A)的定量数据;(C)混合培养的A549和RAW264.7细胞经PyOX(2 μM)处理20分钟后的荧光成像图;收集波长为650-750nm(λex = 633 nm);
图12为不同条件下RAW264.7细胞荧光成像图。(i)为仅被PyOX(2 μM)处理的RAW264.7细胞,(ii-iv)为预先被PyOX(2 μM)处理、随后被2 μM ClO-、SIN-1和H2O2处理的RAW264.7细胞;(v)为预先用LPS(1 mg/mL) /IFN-γ (50 ng/mL)培养12 h、随后经PyOX(2μM)处理的RAW264.7细胞;(vi)为预先用抑制剂ABAH(300 μM)、LPS (1 μg/mL)/IFN-γ (50ng/mL)培养12 h、随后经PyOX(2 μM)处理的RAW264.7细胞,收集波长为650-750nm(λex =633 nm);
图13中(A)荷瘤小鼠经尾静脉或瘤内注射PyOX(20 μM, 50 μL)的活体成像图;(B)为HepG2荷瘤小鼠经尾静脉注射PyOX(20 μM, 50 μL)后荧光随时间变化图;采用630 nm的激发滤光片和700 nm的发射滤光片;
图14为MCF-7荷瘤小鼠暴露的肿瘤和周围正常的组织喷洒PyOX(20 μM)5分钟后的活体成像图。(a)明亮图像;(b)荧光图像;(c)喷洒PyOX后的荧光图像;(d)切除肿瘤后的荧光图像。
具体实施方式
下面将结合本发明实施例,对本发明的技术方案进行清楚、完整地描述,显然,所描述的实施例仅仅是本发明一部分实施例,而不是全部的实施例。基于本发明中的实施例,本领域普通技术人员在没有付出创造性劳动前提下所获得的所有其他实施例,都属于本发明保护的范围。
实施例
基于吡啰红肟的近红外HClO荧光探针的制备,步骤如下:
(1)在0 °C、氮气环境中,将氧杂蒽酮(1.01 g, 3 mmol)溶于无水四氢呋喃(30mL)中,向上述反应液中缓慢加入甲基溴化镁(3.75 mmol)的THF溶液,室温搅拌过夜,反应结束后用水猝灭(50 mL)、DCM萃取(3×50 mL)、减压去除溶剂,得到的产物重新溶解在乙腈和高氯酸的水溶液中,搅拌10分钟后再次用DCM萃取(3×50 mL),有机相用无水Na2SO4干燥,过滤蒸发得到粗产品,柱色谱纯化得到中间体2(1.05 g, 80%)。
1H NMR (600 MHz, CDCl3) δ 7.96 (d, J = 9.6 Hz, 2H), 7.03 (d, J = 9.6Hz, 2H), 6.70 (s, 2H), 3.63 (q, J1 = 7.2 Hz, J2 = 6.6 Hz, 8H), 2.88 (s, 3H),1.34 (t, J = 6.6 Hz, 12H); 13C NMR (150 MHz, CDCl3) δ 152.39, 140.597,123.53, 123.06, 115.71, 115.02, 66.78, 49.03, 21.55; ESI-MS [M+H]+: calcd for337.2274, Found 337.2276.
(2)将步骤(1)得到的中间体2(1.5 g, 3.43 mmol)和I2(0.87 g, 3.44 mmol)溶解于CHCl3,回流反应0.5 h,向上述溶液中加入二甲亚砜(8 mL)继续回流48 h,反应结束后冷却至室温,混合物用饱和Na2S2O3(50 mL)淬灭、二氯甲烷萃取(3×50 mL),有机相经无水Na2SO4干燥、过滤蒸发,柱色谱纯化得到中间体3(0.81 g, 52%);
1H NMR (600 MHz, CDCl3) δ 10.98 (s, 1H), 8.20 (d, J= 9.6 Hz, 2H), 7.12(d, J= 9.6 Hz, 2H), 6.90 (s, 2H), 3.70 (q, J 1 = 7.2 Hz, J 2 = 6.6 Hz, 8H), 1.38(t, J= 6.6 Hz, 12H); 13C NMR (150 MHz, CDCl3) δ 191.35, 158.42, 155.45,140.42, 129.47, 115.69, 111.87, 97.55, 46.43, 12.69; ESI-MS [M+H]+: calcd for351.2067, Found 351.2068.
(3)将步骤(2)得到的中间体3(45 mg, 0.1 mmol)、NH2OH·HCl(69 mg, 1 mmol)和4Å分子筛(5粒)加到乙腈(10 ml)中,室温搅拌6 h,反应液经过滤、水洗、DCM萃取(3×50mL),有机相经干燥、过滤蒸发,柱色谱纯化得到探针PyOX(25 mg, 55%)。
1H NMR (600 MHz, DMSO-d6) δ 13.01 (s, 1H), 9.10 (s, 1H), 8.26(d , J =9.6 Hz, 2H), 7.23 (d, J = 9.6 Hz, 2H), 6.91 (s, 2H), 3.68 (d, J = 6.6, 8H),1.23 (t, J = 6.6 Hz, 12H); 13C NMR (150 MHz, DMSO-d6) δ 157.76, 155.35,144.60, 144.17, 131.49, 114.98, 111.72, 96.60, 45.76, 12.98; ESI-MS [M+H]+:calcd for 366.2176, Found 366.2180.
性能测试
1. 溶液配制
将探针PyOX用乙腈配成2 mM的储液,随后用20 mM的PBS(pH 7.4)稀释至相应浓度。
次氯酸盐溶液(ClO-)用商业化NaClO溶液在去离子水中稀释制备,其浓度通过测量溶液在292 nm处的吸收来确定(ClO-在去离子水中的摩尔消光系数为350 M-1 cm-1)。
过氧亚硝酸盐溶液(ONOO-)根据文献报道制备(R.M. Uppu, W.A. Pryor,Synthesis of peroxynitrite in a two-phase system using isoamyl nitrite andhydrogen peroxide, Anal. Biochem. 1996, 236, 242-249.),其浓度通过测量溶液在302 nm处的吸收来确定(ONOO-溶液在0.1 M NaOH中的摩尔消光系数为1670 M-1 cm-1)。
过氧化氢溶液(H2O2)用商业化H2O2溶液在去离子水中稀释制备。
细胞培养和荧光成像
所有细胞系均购自GeneFull生物技术有限公司(中国)。
所有细胞均培养在37℃、含5%的二氧化碳的培养箱中,其中Raw 264.7细胞和Cos-7细胞培养在含有10%的胎牛血清、100 U /mL青霉素G钠和100 μg/ mL链霉素的RPMI 1640培养基中;A549细胞、HepG2细胞、T98G细胞、BEAS-2B细胞和HUCEC细胞培养在含有10%的胎牛血清、100 U /mL青霉素G钠和100 μg/ mL链霉素的DMEM(高糖)培养基中;进行细胞影像实验前,预先将细胞置于30 mm的玻底细胞培养皿上,静置12小时待细胞贴壁,用磷酸缓冲液(PBS)洗涤细胞3次,然后使用Ceiss LMS 710共聚焦显微镜进行荧光成像,收集波长为650-750 nm (λex = 633 nm)。
3. 细胞毒性
采用CCK-8细胞增殖实验研究探针PyOX的细胞毒性。简单地说,首先将贴壁生长的A549细胞消化为细胞悬液,细胞以每孔5.0×103个细胞的密度接种于96孔板中,用100 μL的DMEM培养基孵育过夜,细胞贴壁。然后将PyOX储液(2 mM)加入到上述培养基中,终浓度保持在0 ~ 10 μM,对照及测试组均重复6次,继续孵育细胞;细胞培养24 h后,弃去旧培养基,PBS洗涤2次,更换含10% CCK-8的新鲜培养基,孵育0.5 h,用iMark TM MicroplateAbsorbance Reader测定450 nm处的吸光度。
4. 亚细胞定位
实验前,将细胞置于30 mm的玻底细胞培养皿上,静置12小时至细胞贴壁,PBS洗涤3次;在37℃、PBS缓冲溶液中,分别用PyOX(2 μM)和LysoTracker Green DND-26(50 nM, 10min)/MitoTracker Green FM(0.2 μM, 10 min)染色细胞,PBS洗涤3次后,进行荧光成像。PyOX的收集波长为650-750 nm (λex = 633 nm),LysoTracker Green DND-26/MitoTracker Green FM的收集波长为500-600 nm (λex = 488 nm)。
活细胞中HClO成像
在影像细胞中外加HClO的实验中,Raw 264.7细胞首先用PyOX(2 μM)预处理20分钟,然后分别用2 μM的ClO-、SIN-1(商品化的ONOO-供体)和H2O2处理20分钟;在影像细胞中内生HClO的实验中,Raw 264.7细胞用LPS (1 μg/mL)/IFN-γ (50 ng/mL)预处理12 h,然后用PyOX(2 μM)处理20分钟,PBS洗涤三次后,进行荧光影像;在抑制实验中,细胞用MPO特异性抑制剂ABAH (300 μM)、LPS (1 μg/mL)/IFN-γ (50 ng/mL) 预处理12 h,然后用PyOX(2μM)处理20分钟,PBS洗涤三次后,进行荧光影像。
用PyOX对荷瘤鼠模型进行肿瘤成像
所有的动物实验都是按照山西大学伦理委员会颁布的相关法律和指南进行的。BALB/c雄性裸鼠(6-8周龄)购自北京维通利华实验动物技术有限公司。
将A549细胞、HepG2细胞或MCF-7细胞(1×106个细胞)经皮下注射于裸鼠左腋(或左腿)处,接种15天后,荷瘤小鼠经尾静脉或瘤内注射PyOX。活体动物成像是在Bruker多模式活体成像系统中进行的,选择630 nm的激发滤光片和700 nm的发射滤光片。
利用PyOX的影像引导切除术
MCF-7荷瘤鼠经解剖暴露出肿瘤及正常组织,暴露肿瘤和周围正常组织喷洒PyOX(2 μM)5分钟进行影像;将肿瘤摘除,再次影像。活体动物成像是在Bruker多模式活体成像系统中进行的,选择630 nm的激发滤光片和700 nm的发射滤光片。
测试结果
1. 水溶性和光稳定性
由于探针在水中具有良好的溶解性(高达60 μM),故体外测试体系均选取纯PBS缓冲体系。首先在PBS(20 mM, pH 7.4)中研究了PyOX(2 μM)与HClO反应前后吸收光谱的变化。如图10A所示,在PBS(20 mM, pH 7.4)中,PyOX的最大吸收峰值为581 nm,明显比经典吡啰红染料的吸收峰长,这是由于肟的吸电子作用增加了染料激发态的分子内电荷转移(ICT)过程;如图9所示,向PyOX溶液中加入ClO-后,探针的最大吸收峰红移至649 nm处,HRMS数据证实,反应生成产物PyCNO(m/z = 365.173)。
在相同条件下,进一步研究了PyOX(2 μM)与HClO反应前后荧光光谱的变化。如图10B所示,由于C=N异构化导致的非辐射跃迁过程,PyOX在PBS中几乎没有荧光;然而,向PyOX溶液中加入ClO-后,在近红外区引起了显著的荧光增强,最大发射峰位于680 nm处,反应可以在10 s内完成。荧光滴定实验表明,ClO-的浓度与680 nm处的荧光强度呈良好的线性关系,检测限低至2.4 nM(图10C)。
此外,PyOX对ClO-的选择性高于其他ROS/RNS以及生物相关阳离子、阴离子和生物硫醇(图10D)。
细胞培养和细胞成像
如图11A所示,用PyOX处理癌细胞,包括A549细胞、HepG2细胞和T98G细胞20分钟后影像,所有细胞均有明亮的红色荧光;而用PyOX处理正常细胞,包括BEAS-2B细胞、HUVEC细胞和COS-7细胞20分钟后影像,所有细胞均显示微弱的荧光。荧光定量分析显示,癌细胞的荧光增强约为正常细胞的3倍(图11B),这表明PyOX有可能根据细胞内ROS水平的差异区分癌细胞和正常细胞。
在癌细胞和正常细胞共培养实验中,A549细胞和RAW264.7细胞在同一共聚焦皿中共同培养24小时,细胞贴壁后用PyOX处理20分钟,然后在共聚焦激光扫描显微镜(CLSM)下影像。如图11C所示,A549细胞(绿色箭头)可见明显的红色荧光信号,而正常的Raw264.7细胞仅可见微弱的荧光(白色箭头),该实验说明PyOX在活体肿瘤诊断中具有一定的潜力。
细胞中HClO的选择性成像和细胞毒性
在RAW264.7细胞中检测了PyOX对HClO的影像能力。如图12所示,预先孵化PyOX的RAW264.7细胞用633 nm的激光激发时,红色荧光几乎可以忽略;当预先孵化PyOX的RAW264.7细胞继续孵化几种具有代表性的ROS时,只有HClO能诱导细胞发出明亮的红色荧光;当RAW264.7细胞预先被LPS诱导12 h,继续孵化PyOX后,可以观察到明亮的红色荧光。这些结果表明,PyOX具有良好的细胞膜通透性,并且可以选择性影像细胞内源性及外源性的HClO。
此外,CCK-8细胞增殖实验研究结果显示,PyOX在0-10 μm的浓度范围内具有较低的细胞毒性,细胞存活率大于85%。
4. 肿瘤成像
分别将PyOX(20 μM, 50 μL)经皮下注射到A549荷瘤鼠、HepG2荷瘤鼠和MCF7荷瘤鼠的肿瘤区域及正常组织区域,随后在小动物活体成像系统下成像。如图13A所示,肿瘤区域显示出明显的荧光信号,而正常组织区域显示出微弱的荧光信号;另外,将PyOX(20 μM,50 μL)经尾静脉注射到HepG2荷瘤鼠体内,只有肿瘤区域出现了显著的荧光信号,该信号在10 min时达到最大,30 min后由于代谢逐渐消失(图11B)。这些结果表明,由于癌细胞本底的ROS水平高于正常细胞,PyOX可以选择性影像荷瘤鼠的肿瘤部位。
利用PyOX的影像引导切除术
如图14所示,将PyOX喷洒于暴露的肿瘤和周围正常组织,只有肿瘤区域出现明亮的荧光信号,而周围正常组织的荧光可以忽略;将小鼠的肿瘤完全切除后,在剩余的组织中几乎看不到荧光。结果表明,PyOX在外科肿瘤切除术中有很好的应用前景。
以上所述仅为本发明的较佳实施例而已,并不用以限制本发明,凡在本发明的精神和原则之内,所作的任何修改、等同替换、改进等,均应包含在本发明的保护范围之内。
Claims (8)
2.权利要求1所述的荧光探针的制备方法,其特征在于步骤如下:
(1)在0 °C、氮气环境中,将氧杂蒽酮溶于无水四氢呋喃中,向上述反应液中缓慢加入甲基溴化镁的THF溶液,室温下搅拌过夜,反应结束后用水猝灭、DCM萃取、减压去除溶剂,得到的产物重新溶解在乙腈和高氯酸的水溶液中,搅拌10分钟后再次用DCM萃取,有机相用无水Na2SO4干燥,过滤蒸发得到粗产品,柱色谱纯化得到中间体2;
(2)将步骤(1)得到的中间体2和I2溶解于CHCl3,回流反应0.5 h,向上述溶液中加入二甲亚砜继续回流48 h,反应结束后冷却至室温,混合物用饱和Na2S2O3淬灭、二氯甲烷萃取,有机相经无水Na2SO4干燥、过滤蒸发,柱色谱纯化得到中间体3;
(3)将步骤(2)得到的中间体3、NH2OH·HCl和4Å分子筛加到乙腈中,室温搅拌6 h,反应液经过滤、水洗、DCM萃取,有机相经干燥、过滤蒸发、柱色谱纯化得到探针PyOX。
6.根据权利要求2-5任一项所述的荧光探针的制备方法,其特征在于:所述步骤(1)中氧杂蒽酮化合物和甲基溴化镁的摩尔比为1:1.25;步骤(2)中间体2和I2的摩尔比为1:1,步骤(3)中间体3和NH2OH·HCl的摩尔比为1:10。
7.权利要求1所述的荧光探针在近红外区域检测HClO的应用,最低检测限为2.4 nM。
8.权利要求1所述的荧光探针在区分癌细胞和正常细胞中的应用,其特征在于:通过检测细胞内ROS水平区分癌细胞和正常细胞。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011361513.7A CN112500386B (zh) | 2020-11-27 | 2020-11-27 | 基于吡罗红肟的近红外HClO荧光探针、制备及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011361513.7A CN112500386B (zh) | 2020-11-27 | 2020-11-27 | 基于吡罗红肟的近红外HClO荧光探针、制备及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN112500386A true CN112500386A (zh) | 2021-03-16 |
CN112500386B CN112500386B (zh) | 2022-02-08 |
Family
ID=74967945
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202011361513.7A Active CN112500386B (zh) | 2020-11-27 | 2020-11-27 | 基于吡罗红肟的近红外HClO荧光探针、制备及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112500386B (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113354612A (zh) * | 2021-06-15 | 2021-09-07 | 郑州大学 | 基于吡罗红的线粒体和核仁rna近红外荧光探针、制备及应用 |
CN113945552A (zh) * | 2021-10-20 | 2022-01-18 | 延边大学 | 一种活细胞线粒体中还原型谷胱甘肽的浓度测定方法 |
CN114478308A (zh) * | 2022-01-25 | 2022-05-13 | 南京林业大学 | 一种用于检测次氯酸的樟脑基酮肟类荧光探针及其制备方法和应用 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106905310A (zh) * | 2017-03-09 | 2017-06-30 | 济南大学 | 一种检测次氯酸的荧光探针及其制备方法和应用 |
-
2020
- 2020-11-27 CN CN202011361513.7A patent/CN112500386B/zh active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106905310A (zh) * | 2017-03-09 | 2017-06-30 | 济南大学 | 一种检测次氯酸的荧光探针及其制备方法和应用 |
Non-Patent Citations (6)
Title |
---|
MITSUYASU KAWAGUCHI等: "Development and cellular application of visiblelight-controllable HNO releasers based on caged Piloty’s acid", 《CHEM. COMMUN.》 * |
MONICA PENGSHUNG等: "Bathochromically shifted polymethine dyes through silicon incorporation", 《CHEMRXIV》 * |
XIAOHONG CHENG等: "A "turn-on" fluorescent probe for hypochlorous acid: convenient synthesis, good sensing performance, and a new design strategy by the removal of C=N isomerization", 《CHEM. COMMUN.》 * |
ZHIQUAN LI等: "Coumarin-Based Oxime Esters: Photobleachable and Versatile Unimolecular Initiators for Acrylate and Thiol-Based Click Photopolymerization under Visible Light-Emitting Diode Light Irradiation", 《ACS APPL. MATER. INTERFACES》 * |
刘云龙: "罗丹明荧光探针的设计、合成及光谱研究", 《中国博士学位论文全文数据库工程科技Ⅰ辑》 * |
郭炜等: "近红外罗丹明荧光染料", 《山西大学学报(自然科学版)》 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113354612A (zh) * | 2021-06-15 | 2021-09-07 | 郑州大学 | 基于吡罗红的线粒体和核仁rna近红外荧光探针、制备及应用 |
CN113945552A (zh) * | 2021-10-20 | 2022-01-18 | 延边大学 | 一种活细胞线粒体中还原型谷胱甘肽的浓度测定方法 |
CN114478308A (zh) * | 2022-01-25 | 2022-05-13 | 南京林业大学 | 一种用于检测次氯酸的樟脑基酮肟类荧光探针及其制备方法和应用 |
Also Published As
Publication number | Publication date |
---|---|
CN112500386B (zh) | 2022-02-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN112500386B (zh) | 基于吡罗红肟的近红外HClO荧光探针、制备及其应用 | |
CN110283583B (zh) | γ-谷氨酰转肽酶响应型分子探针及其应用 | |
Li et al. | A near-infrared fluorescent probe for Cu2+ in living cells based on coordination effect | |
CN110981842B (zh) | 一种区分正常细胞和癌细胞的特异性检测脂滴的荧光探针及应用 | |
CN102746313A (zh) | 含1,2,4-三唑结构单元的罗丹明b酰肼衍生物及其制备方法与应用 | |
US10351707B2 (en) | Water-soluble iron ion fluorescent probe and preparation method thereof | |
CN106947467B (zh) | 一种检测精氨酸的上转换发光纳米传感材料及在精氨酸检测中的应用 | |
CN103896928B (zh) | 一种pH荧光化学传感器及其合成方法和应用 | |
Song et al. | A turn-on fluorescent probe for Au 3+ based on rodamine derivative and its bioimaging application | |
Yang et al. | Red/NIR neutral BODIPY-based fluorescent probes for lighting up mitochondria | |
US20140045171A1 (en) | Benzoxazole-based fluorescent metal ion indicators | |
Karakuş et al. | A guanidinium modified rhodamine-based fluorescent probe for in vitro/vivo imaging of gold ions | |
CN110885675A (zh) | 纳米荧光探针及制备方法与其在检测高尔基体中hno的应用 | |
Wu et al. | Novel near-infrared frequency up-conversion luminescence probe for monitoring biothiols in vitro and in vivo | |
CN111778014A (zh) | β-半乳糖苷酶近红外荧光探针及其制备方法和用途 | |
CN112694469B (zh) | 基于吡罗红肼的HOCl荧光探针、制备方法及应用 | |
CN113788821B (zh) | 近红外联氨化合物、制备方法以及甲醛检测试剂盒和应用 | |
CN107793386B (zh) | 荧光探针及其制备方法和用途 | |
CN112574246B (zh) | Zn2+比率荧光探针、制备及应用 | |
CN114478473B (zh) | 一种亮氨酸氨基肽酶化学发光检测试剂的合成及应用 | |
CN114437053A (zh) | 一种纳米探针与其在检测高尔基体中超氧阴离子的应用 | |
CN109651336B (zh) | 一种基于药物分子的检测硫化氢荧光探针及其制备方法 | |
CN115873011B (zh) | 一种癌细胞靶向的响应线粒体内硝基还原酶的荧光探针及其制备方法和用途 | |
CN110066290A (zh) | 一种有机硅席夫碱荧光探针及其应用 | |
CN115340517B (zh) | 一种极性敏感阳离子荧光染料及其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |